美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Emera Inc.

49.01

-0.1800-0.37%

成交量：26.96萬

成交額：1,320.30萬

市值：149.86億

市盈率：21.98

高：49.44

開：49.44

低：48.74

收：49.19

52周最高：55.49

52周最低：45.77

股本：3.06億

流通股本：3.06億

量比：0.75

換手率：0.09%

股息：2.10

股息率：4.29%

每股收益(TTM):2.23

每股收益(LYR):2.47

淨資產收益率：7.56%

總資產收益率：2.91%

市淨率：1.61

市盈率(LYR):19.88

資料載入中...

總覽公司新聞資訊公告

伯維（ABBV）向EMA遞交Skyrizi克羅恩病治療上市申請

中化國際EMA項目投產

分析師：比特幣已觸及長期下行趨勢線及 21 個月 EMA 均線，站穩當前阻力線方能確認漲勢

奧麥羅斯2026財年第二季度業績：YARTEMLEA推動運營實現收支平衡

TradingKey中文

Emera（EMA）上半年調整後淨利潤增至6.27億加元、淨收入降至6.67億加元

財報前瞻｜Emera Inc.本季度營收預計增15.89%，機構觀點偏謹慎

瑞博生物-B：核心產品VORTOSIRAN針對SPAF的2B期臨床試驗獲EMA批准

歐洲藥品管理局（EMA）：阿斯利康(AZN.US)已撤回其重磅免疫藥物Imfinzi在歐盟的擴展適應症申請。

Rocket Lab股價站穩200日EMA上方：獲NASA合同後是否值得買入？

环球市场播报

恒瑞醫藥(600276.SH)：瑞維魯胺片上市許可申請獲EMA受理

新聞稿：CosmoFarm公布2026年第二季度創紀錄營收超1500萬美元，年化運行率超6000萬美元；新增超80家藥房並擴展AI自動化與設施產能

從跟隨者到定價者：加密市場的角色正在反轉

財報前瞻｜Emera Inc.本季度營收預計增35.49%，盈利質量成看點

羅氏獲歐洲監管機構反饋後，啓動Elevidys基因療法新研究

环球市场播报

港股異動 | 和譽-B(02256)盤中漲近10% FGFR4抑制劑依帕戈替尼獲EMA授予孤兒藥資格

和譽-B(02256)：FGFR4抑制劑依帕戈替尼獲EMA授予孤兒藥資格，用於治療肝細胞癌

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/EMA/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":49.01,"timestamp":1789416000000,"preClose":49.19,"halted":0,"volume":269646,"delay":0,"changeRate":-0.0036592803415328263,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"盤前交易","change":-0.18,"latestTime":"09-15 05:00:00 EDT","open":49.44,"high":49.44,"low":48.74,"amount":13202976.405059999,"amplitude":0.014231,"askPrice":49.68,"askSize":12,"bidPrice":48.51,"bidSize":19,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789479000000},"marketStatusCode":1,"adr":0,"exchange":"NYSE","adjPreClose":49.01,"dividendRate":0.043027,"postHourTrading":{"tag":"盘后","latestPrice":49.01,"preClose":49.01,"latestTime":"19:30 EDT","volume":76980,"amount":3775612.197408,"timestamp":1789428606154,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7469087244946484,"impliedVol":0.4029,"impliedVolPercentile":0.976},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":0.7469087244946484,"shares":305783111,"dividePrice":2.101649,"high":49.44,"amplitude":0.014231,"preClose":49.19,"low":48.74,"week52Low":45.77,"pbRate":"1.61","psRate":"2.33","week52High":55.49,"institutionHeld":0,"latestPrice":49.01,"committee":0.225806,"eps":2.229761,"divideRate":0.042882,"volume":269646,"delay":0,"ttmEps":2.229761,"open":49.44,"prevYearClose":49.24,"prevWeekClose":49.19,"prevMonthClose":50.09,"prevQuarterClose":53.02,"fiveDayClose":50.35,"twentyDayClose":51.51,"sixtyDayClose":51.75,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"盤前","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"盤前","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"盤前","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778472000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-09-11","current":21.979934,"percent":0.489097,"low":16.637027,"twenty":17.708223,"median":20.275847,"eighty":21.041773,"high":22.07626,"avg":19.825742,"sd":1.478156,"marketCap":15223834714.33},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-28","current":20.499692,"twenty":17.645049,"median":20.225489,"eighty":21.044992,"marketCap":15379168560.24},{"date":"2026-09-04","current":20.473108,"twenty":17.659944,"median":20.257815,"eighty":21.043803,"marketCap":15442660903.12},{"date":"2026-09-11","current":20.227938,"twenty":17.708223,"median":20.275847,"eighty":21.041773,"marketCap":15223834714.33}],"updateTime":1789451793256},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662639772","title":"伯維（ABBV）向EMA遞交Skyrizi克羅恩病治療上市申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2662639772","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662639772?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 16:56","pubTimestamp":1787821007,"startTime":"0","endTime":"0","summary":"Skyrizi此前已经在银屑病、银屑病关节炎等多个自身免疫疾病领域拿到欧洲地区的获批资质，如若本次克罗恩病适应症顺利获批，将进一步拓宽该产品在欧洲炎症性肠病赛道的市场空间。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305377","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0472753341.HKD","IYH","LU1585245621.USD","LU2237443622.USD","AGNG","LU2087621335.USD","LU2133065610.SGD","SG9999011175.SGD","LU2023251221.USD","LU2089283258.USD","LU2125909593.SGD","MEDX","SG9999001440.SGD","LU0234572021.USD","IPOS","JDOC","FHLC","IE0004445239.USD","GLAM","LU0058720904.USD","LU0198837287.USD","PJP","VHT","LU2125909247.SGD","LU0661504455.SGD","ABBV","LU1236620834.HKD","FTXH","LU0965508806.USD","LU0882574055.USD","LU1989771016.USD","PPH","BK4559","EMA","LU0417517546.SGD","IXJ","IE000F7OJYX1.SGD","LU1732799900.SGD","BK4533","IE00BLSP4239.USD","LU1839511570.USD","LU0128525929.USD","TRUH","LU1236620750.USD","XLV","RXL","LU0985320562.USD","LU0114720955.EUR","LU1267930573.SGD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662200130","title":"中化國際EMA項目投產","url":"https://stock-news.laohu8.com/highlight/detail?id=2662200130","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662200130?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 10:09","pubTimestamp":1787623784,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661483293","title":"分析師：比特幣已觸及長期下行趨勢線及 21 個月 EMA 均線，站穩當前阻力線方能確認漲勢","url":"https://stock-news.laohu8.com/highlight/detail?id=2661483293","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661483293?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 21:18","pubTimestamp":1787318280,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，加密分析师 Rekt Capital 发布比特币技术图表分析指出，比特币正遭遇宏观下行趋势线阻力，该趋势线与 21 个月 EMA 均线拟合。Rekt Capital 认为，如果比特币在这个拟合的阻力区域受阻，那么可能在 50 个月 EMA 均线处（紫色）获得支撑。总体而言，比特币需要将这两个宏观 EMA 重新转化为新的支撑位，并突破宏观下行趋势线，以确认新一轮牛市。Rekt Capital 系资深加密技术分析师，在 X 平台拥有 56 万粉丝。 ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2284491","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BETH","MSTU","SBIT","BTFX","03008","NCIQ","CRPT","BRRR","GBTC","03439","YBIT","STCE","BTCZ","BITC","NGHT","ARKY","BTRN","BTCI","BITU","HODL","BITX","09042","BEGS","FBTC","YBTC","BTF","OOQB","CBTJ","BITI","BTYB","BETE","EMA","DAPP","MSBT","BITQ","BKCH","BTC.USD.CC","MBTmain","SMST","IBIT","WGMI","BTGD","BITW","BTC.USD.HKCC","BTCL","MAXI","GDLC","LFGY","HECO","BTCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659183413","title":"奧麥羅斯2026財年第二季度業績：YARTEMLEA推動運營實現收支平衡","url":"https://stock-news.laohu8.com/highlight/detail?id=2659183413","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659183413?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 04:18","pubTimestamp":1786565932,"startTime":"0","endTime":"0","summary":"Omeros公布2026财年第二季度产品销售净额为2850万美元，高于去年同期的零，主要得益于YARTEMLEA总收入达到3220万美元，较第一季度增长190%。按GAAP计算的净利润为1320万美元，每股基本收益为0.18美元，但其中包含1150万美元的非现金公允价值收益；非GAAP调整后净利润为180万美元。经营活动产生现金410万美元，而在7月份完成6020万美元的可转换票据回购之前，截至6月底的现金及短期投资总额为1.32亿美元。","market":"other","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock5.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/earnings/262100447-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER","BK4208","LU0949170772.SGD","LU0868494708.USD","LU0203347892.USD","LU2346227817.USD","LU1894683264.USD","NTAP","LU2500361329.USD","LU1894683348.USD","LU0553294199.USD","BK4087","LU0868494617.USD","BK4588","EMA","CEO","LU1003077747.HKD","CHMP","LU0661504455.SGD","LU0545039389.USD","BK4081","LU0738911758.USD","SG9999001440.SGD","LU0203345920.USD","BK4585","LU0942090050.USD","CMS","LU2637428348.USD","BK4170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657648031","title":"Emera（EMA）上半年調整後淨利潤增至6.27億加元、淨收入降至6.67億加元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657648031","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657648031?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 19:34","pubTimestamp":1786102483,"startTime":"0","endTime":"0","summary":"金吾财讯 | 北美能源巨头Emera 公布2026年第二季度及上半年财务业绩。2026年二季度，Emera实现调整后净利润2.12亿加元，较上年同期的2.36亿加元有所放缓；净利润为1.05亿加元。2026年上半年，公司调整后净利润达到6.27亿加元，高于2025年上半年的6.15亿加元。期内净收入为6.67亿加元，低于去年同期的7.18亿加元。展望未来，公司预计，2026年调整后每股收益增长将超越其5%-7%的年度目标区间高位，公司重申截至2030年维持5%-7%的复合年均增长承诺。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303564","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148281703","title":"財報前瞻｜Emera Inc.本季度營收預計增15.89%，機構觀點偏謹慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1148281703","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148281703?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 08:42","pubTimestamp":1785458557,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年08月07日盘前发布第二季度财报，市场预期营收增长而利润承压，投资者关注盈利质量与现金流稳定性。一致预期显示，本季度Emera Inc.营收为20.29亿加元，同比增长15.89%；调整后每股收益为0.49加元，同比下降24.17%；EBIT为4.73亿加元，同比增长1.23%，上一季度未披露针对本季度的明确量化指引。上季度公司实现营收28.13亿加元，同比增长5.12%；毛利率50.20%；归属于母公司股东的净利润5.82亿加元，净利率20.69%；调整后每股收益同比增长7.00%，净利润环比增长568.97%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜Emera Inc.本季度营收预计增15.89%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001188","title":"瑞博生物-B：核心產品VORTOSIRAN針對SPAF的2B期臨床試驗獲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001188?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 19:59","pubTimestamp":1785239982,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","BK4081","IBBJ","MDTX","BMED","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653608566","title":"歐洲藥品管理局（EMA）：阿斯利康(AZN.US)已撤回其重磅免疫藥物Imfinzi在歐盟的擴展適應症申請。","url":"https://stock-news.laohu8.com/highlight/detail?id=2653608566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653608566?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 18:07","pubTimestamp":1784887647,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","AZNH","LU0289739699.SGD","BK4585","LU2462157665.USD","LU0320765992.SGD","LU2237443549.SGD","LU2417539215.USD","BK4081","LU0058720904.USD","AZN","BK4568","LU0109394709.USD","LU0310800379.SGD","LU1829250122.USD","LU0029864427.USD","LU2237443978.SGD","LU2237443895.HKD","LU2237443622.USD","LU2237443465.HKD","LU2468319806.SGD","LU1267930573.SGD","LU2237443382.USD","LU2456880835.USD","IE00B3T34201.USD","LU0432979614.USD","LU0708994859.HKD","LU0128525929.USD","LU2089984988.USD","LU2236285917.USD","BK4007","LU0889565916.HKD","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647037238","title":"Rocket Lab股價站穩200日EMA上方：獲NASA合同後是否值得買入？","url":"https://stock-news.laohu8.com/highlight/detail?id=2647037238","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647037238?lang=zh_tw&edition=fundamental","pubTime":"2026-06-29 21:09","pubTimestamp":1782738540,"startTime":"0","endTime":"0","summary":"Rocket Lab股价周一盘前交易时段上涨，此前该公司宣布将收购卫星通信运营商Iridium，交易价值约80亿美元。这一消息叠加近期获得的NASA发射合同，为股价提供了技术面支撑。　　从技术走势来看，Rocket Lab股价在6月25日跌至80.69美元的低点后获得支撑，目前盘前交易于90美元附近，成功站稳200日指数移动平均线上方。　　上周，NASA宣布选择Rocket Lab执行三项Electron火箭发射任务，用于PolSIR和TSIS-2科学任务，预计于2027年初启动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-29/doc-inifauhn5315358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0217","BK4081","300785","NASA","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645409710","title":"恒瑞醫藥(600276.SH)：瑞維魯胺片上市許可申請獲EMA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2645409710","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645409710?lang=zh_tw&edition=fundamental","pubTime":"2026-06-22 16:38","pubTimestamp":1782117505,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司收到了欧洲药品管理局(European Medicines Agency，简称“EMA”)的通知,EMA正式确认并受理公司递交的瑞维鲁胺片的上市许可申请，这是公司首个自主研发的创新药向欧盟递交上市申请。该药品适用于联合雄激素剥夺治疗(ADT)，治疗高瘤负荷的转移性激素敏感性前列腺癌(mHSPC)成年男性患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600276","LU1328615791.USD","LU1781817850.SGD","LU2495084118.USD","LU2543165471.USD","LU2328871848.SGD","LU1064131003.USD","LU2580892862.HKD","LU2289578879.USD","LU1997245177.USD","LU2097828805.USD","BK0183","BK0188","LU1146622755.USD","LU2097828474.EUR","IPOS","BK4081","LU1255011170.USD","BK0196","01276","LU0405327148.USD","BK0012","LU2097828557.USD","LU0359201885.HKD","BK1191","LU1997244956.HKD","EMA","BK0060","LU0359202008.SGD","LU1023057109.AUD","LU1655091616.SGD","LU0405327494.USD","LU2148510915.USD","LU1997245094.SGD","LU1580142542.USD","LU2097828714.EUR","LU1820825898.SGD","LU2580892789.USD","LU0359201612.USD","LU1064130708.USD","LU2488822045.USD","BK0028","LU2097828631.EUR","LU1969619763.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178964593","title":"新聞稿：CosmoFarm公布2026年第二季度創紀錄營收超1500萬美元，年化運行率超6000萬美元；新增超80家藥房並擴展AI自動化與設施產能","url":"https://stock-news.laohu8.com/highlight/detail?id=1178964593","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178964593?lang=zh_tw&edition=fundamental","pubTime":"2026-06-19 03:35","pubTimestamp":1781811307,"startTime":"0","endTime":"0","summary":"Cosmos Health Inc.今日宣布，其全资子公司CosmoFarm S.A.在2026年第二季度实现了超过1500万美元的创纪录营收，这相当于超过6000万美元的年化运行率。Cosmos Health是一家业务多元化、垂直整合的全球医疗健康集团。在此期间，CosmoFarm在其分销网络中新增了超过80家药房，延续了强劲的客户增长势头，这使其已成为大雅典地区领先的医药批发商之一。为了支持这一加速增长，Cosmos Health正在增加CosmoFarm的资本支出，投资于新的机器人自动化与人工智能系统，以优化采购、库存管理和订单履行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COSM","BK4081","ARTY","BK4232","CHAT","BK4175","AIPO","R","EMA","AGIX","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637806473","title":"從跟隨者到定價者：加密市場的角色正在反轉","url":"https://stock-news.laohu8.com/highlight/detail?id=2637806473","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637806473?lang=zh_tw&edition=fundamental","pubTime":"2026-05-21 12:09","pubTimestamp":1779336566,"startTime":"0","endTime":"0","summary":" 加密平台在 CBRS 上市前成功实现了精准的先期定价，这表明 Crypto 正凭借创新机制，逐步从传统金融的跟随者转变为全球资产的新定价中枢。 ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2266266","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","CBRS","EMA","FAZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185761853","title":"財報前瞻｜Emera Inc.本季度營收預計增35.49%，盈利質量成看點","url":"https://stock-news.laohu8.com/highlight/detail?id=1185761853","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185761853?lang=zh_tw&edition=fundamental","pubTime":"2026-05-01 08:17","pubTimestamp":1777594630,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年05月08日公布最新季度业绩，市场关注营收增速与成本控制的落地情况。根据一致预期，本季度Emera Inc.营收预计为30.09亿加元，同比增长35.49%；调整后每股收益预计为1.15加元，同比增长15.55%；息税前利润预计为7.02亿加元，同比增长7.05%；当前一致预期未提供本季度毛利率及净利润或净利率的具体预测。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Emera Inc.本季度营收预计增35.49%，盈利质量成看点","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627213629","title":"羅氏獲歐洲監管機構反饋後，啓動Elevidys基因療法新研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2627213629","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627213629?lang=zh_tw&edition=fundamental","pubTime":"2026-04-16 20:44","pubTimestamp":1776343440,"startTime":"0","endTime":"0","summary":"罗氏公司周四宣布，在收到欧洲药品监管机构的反馈后，将针对其基因疗法 Elevidys 启动一项晚期临床试验。该疗法用于治疗杜氏肌营养不良症，由罗氏与美国 Sarepta Therapeutics 公司合作研发。此前，因两例患者死亡事件与该疗法相关而引发审查，这款药物去年未能获得欧洲药品管理局的批准。Elevidys 目前已在 9 个国家获批用于可自主行走、确诊携带 DMD 基因突变的男孩，其中包括美国。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-16/doc-inhuszrw2800982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624593383","title":"港股異動 | 和譽-B(02256)盤中漲近10% FGFR4抑制劑依帕戈替尼獲EMA授予孤兒藥資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2624593383","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624593383?lang=zh_tw&edition=fundamental","pubTime":"2026-04-01 15:57","pubTimestamp":1775030256,"startTime":"0","endTime":"0","summary":"消息面上，和誉宣布，其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格，用于治疗肝细胞癌。目前，依帕戈替尼正在全球多地开展临床研究，此次获EMA授予ODD，将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。除本次获得EMA孤儿药资格外，依帕戈替尼此前还分别获得了美国食品药品监督管理局授予的ODD和快速通道资格认定，以及中国国家药品监督管理局授予的突破性疗法认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BPRC5H50.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU2488822045.USD","VXUS","LU2476274308.USD","BK4585","BK4588","02256","EMA","LU2778985437.USD","LU2476274720.SGD","BK1161","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623581546","title":"和譽-B(02256)：FGFR4抑制劑依帕戈替尼獲EMA授予孤兒藥資格，用於治療肝細胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2623581546","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623581546?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 20:32","pubTimestamp":1774960347,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，公司附属公司上海和誉生物医药科技有限公司宣布，其自主研发的高选择性口服小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格，用于治疗肝细胞癌。目前，依帕戈替尼正在全球多地开展临床研究，此次获EMA授予ODD，将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IE00B543WZ88.USD","BK4081","IE00BPRC5H50.USD","LU2778985437.USD","02256","LU2476274308.USD","LU2476274720.SGD","LU2488822045.USD","IE00B5MMRT66.SGD","EMA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}